INTRODUCTION
Dyslipidemia is a core characteristic of the metabolic syndrome, and is an important risk factor for athero sclerosis, coronary heart disease, stroke and other cardiovascular and cerebrovascular diseases. It is also closely related to many significant diseases such as diabetes and nephropathy [1] . Dyslipidemia is divided into two types, referred to as primary and secondary dyslipidemia. Primary dyslipidemia has a genetic history and may be caused by congenital enzyme defects. Secondary dyslipidemia is usually present in patients with diseases such as diabetes mellitus, hypothyroidism, nephrotic syndrome, biliary obstruction, pancreatitis, gout, alcoholism, and various liver disorders [2] . The im provement in living standards and associated lifestyle changes have led to dyslipidemia being considered one of the most important risk factors for metabolic diseases worldwide [3] . Therefore, management of dyslipidemia is of vital importance to prevent and cure a variety of acute and chronic human diseases.
The commonly used lipid regulators include statins, fibrates, nicotinic acid and variants, bile acid sequestrants and inhibitors of cholesterol absorption. These drugs can be effective for treating dyslipidemia, but have signi ficant adverse effect profiles [4] . For example, statins may increase blood glucose concentrations, cause rhabdo myolysis or damage the liver and kidneys [5] . Traditional Chinese medicines (TCMs) are one of the world's oldest herbal medicines and have been applied extensively by TCM practitioners for thousands of years [6] . TCMs have an indispensable role in the prevention and treatment of human diseases, especially those that are complicated and chronic [7] . As a complementary therapy technique with fewer side effects than Western medicines, TCMs have been employed widely to regulate lipid metabolic disorders [8] . Thus, TCMs may serve as the basis for devel opment of new lipidregulating drugs or health products.
Rhizoma polygonati, first recorded in Mingyi Bielu in 220450 AD (written by HongJing Tao), has been used as a TCM and nutritional food for over 2000 years. Polygonatum kingianum Coll. et Hemsl., Polygonatum sibiricum Red. and Polygonatum cyrtonema Hua are described in the Chinese Pharmacopoeia (2015 edition) as legal sources of Rhizoma polygonati. Polygonatum kingianum (P. kingianum; Figure 1 ) is mainly distributed in the Chinese provinces of Yunnan, Sichuan, Guizhou and Guangxi. It is mainly comprised of saponins and polysaccharides, and has pharmacological activities that include immune system stimulation, antiaging effects and blood glucose regulation [9, 10] . Our previous research showed that the total saponins and total polysaccharides from P. kingianum had blood glucose and lipid regulating activities [11, 12] . However, the lipidregulating effects of P. kingianum and the mechanism for these remain unclear.
Metabolomics can comprehensively characterize small molecule metabolites in biological systems. It can also provide an overview of metabolic status and global biochemical events after external stimulation such as in disease models and after drug treatment [13] . Meta bolomics is a novel method in pharmacological and phar macodynamic studies that is increasingly employed to assess the therapeutic and toxic effects of herbal TCMs and TCM prescriptions, and their mechanism of action [14] .
In the present study, we investigated the lipidregu lating effects and the underlying mechanism of action of P. kingianum on highfat diet (HFD)induced dyslipidemia in rats. An integrated untargeted metabolomic method was used, which was based on ultrahigh performance liquid chromatography/mass spectrometry (UHPLC/MS) analysis of serum, urine and liver samples ( Figure 2 ). The results indicated that P. kingianum alleviated HFD induced dyslipidemia by regulating many endogenous metabolites in serum, urine and liver samples. Taken together, these findings indicated that P. kingianum may be a promising lipid regulator to treat dyslipidemia and further alleviate associated diseases.
MATERIALS AND METHODS

Chemicals, reagents and materials
Kits for quantifying triglyceride (TG) and total cholesterol (TC) concentrations were purchased from ZhongshengBei Biotech Co., Ltd. (Beijng, China). Bicinchoninic Acid (BCA) Protein Determination Kit was obtained from Beyotime Institute of Biotechnology (Shanghai, China). Simvastatin was purchased from Hangzhou Merck East Pharmaceutical Co., Ltd. (Hangzhou, China). HPLCgrade formic acid and acetonitrile were acquired from Merck (Darmstadt, Germany). Basal rodent diet (calories provided from carbohydrates, proteins and fat were 62%, 26% and 12%, respectively) was obtained from Suzhou Shuangshi Experimental Animal Feed Technology Co., Ltd. (Suzhou, China). Cholesterol, refined lard, and eggs were supplied by Beijing Boao Extension Co., Ltd. (Beijing, China), Sichuan Green Island Co., Ltd. (Chengdu, China) and WalMart Supermarket (Kunming, China), respectively. Highpurity deionized water was purified using a Milli-Q system (Millipore, Bedford, MA, United States). All other reagents were of analytical grade or higher. 
Preparation of P. kingianum extract
P. kingianum rhizome was processed according to regulations in the Chinese Pharmacopoeia (2015 edition). Briefly, fresh P. kingianum rhizome was separated from fibrous roots, washed, cut into thick slices and dried at 50 ℃. The dried materials were then infiltrated in a 5-fold volume of Shaoxing rice wine (Beijing Ershang Wangzhihe Food Co., Ltd., Beijing, China), and then placed in a steam sterilizer (LDZX-50 KBS, Shanghai Shenan Medical Instrument Factory, Shanghai, China) at 120 ℃ for 2.5 h. After cooling for 3 h, the steamed materials were dried at 60 ℃.
The steamed and dried P. kingianum sample was pulverized, immersed in a 7fold volume of water for 30 min and then decocted with water for 60 min. The filtrates were collected after leaching. The dregs were decocted successively with a 7fold volume of water for a further 60 min, and the extracted liquids filtered. The two filtrates were then combined and condensed using an R-210 rotatory evaporator (Büchi Labortechnik AG, Flawil, Switzerland) under reduced pressure at 50 ℃.
Finally, the concentrates were lyophilized to a powder using a FD53 freeze dryer (SIM International Group Co. Ltd., Newark, DE, United States). The obtained sample powder was stored in a desiccator at room temperature until use.
Animal experiments
Healthy male SpragueDawley rats (200 ± 50 g) were obtained from Dashuo Biotech. Co., Ltd. (Chengdu, China). They were adjusted to a controlled environment (22 ± 1 ℃ temperature; 60% ± 10% humidity; and a 12 h/12 h light/dark cycle) with free access to water and a commercial laboratory complete food. Experiments complied with the Guide for the Care and Use of Laboratory Animals as published by the United States of America National Institutes of Health and specifically approved by the Institutional Ethical Committee on Animal Care and Experimentations of Yunnan University of Traditional Chinese Medicine (R062016003) (Kunming, China). All reasonable efforts were made to minimize animal suffering.
After one week of adaptive feeding, rats were randomized into four groups (n = 5 rats per group): normal control (normal saline), model (normal saline), simvastatin [1.8 mg/(kg•d)] and P. kingianum [4 g/(kg•d)] groups. The simvastatin group served as a positive control. The rats were given the treatments intragastrically once a day for 14 consecutive weeks. Simvastatin and P. kingianum were prepared separately in normal saline. Dyslipidemia was induced with an HFD (comprised of 1% cholesterol, 10% refined lard, 10% and resting at 4 ℃ for 20 min, the samples were centrifuged at 12000 rpm and 4 ℃ for 15 min. The collected supernatants were dried under a gentle nitrogen stream. The obtained residues were redissolved in 100 μL of acetonitrile for metabolomics analysis.
Urine samples: Samples were lyophilized to a powder using a FD53 freeze dryer (SIM International Group Co. Ltd., Newark, DE, United States). The obtained sample powders were dissolved with 100 μL of water and then diluted with 300 μL of acetonitrile. After vortexmixing and resting at 4 ℃ for 20 min, the samples were centrifuged at 12000 rpm and 4 ℃ for 15 min. The collected supernatants were dried with a gentle nitrogen stream. The residues were redissolved in 100 μL of acetonitrile for metabolomics analysis.
Liver samples: Samples were thawed at room tempe rature before pre-treatment. Liver tissue (0.2 g) from each rat was homogenized with 1.0 mL of normal saline and then diluted with 300 μL of acetonitrile. After vortexmixing and resting at 4 ℃ for 20 min, the samples were centrifuged at 12000 rpm and 4 ℃ for 15 min. The collected supernatants were dried with a gentle nitrogen stream. The residues were redissolved in 100 μL of acetonitrile for metabolomics analysis.
Conditions of UHPLC/MS analysis
UHPLC/MS analyses were performed on an UHPLC Dionex Ultimate 3000 system coupled with a Thermo eggs and 79% basic feed) for 14 wk in all groups except for the normal control group.
Sample collection
To collect urine samples, rats in each experimental group were housed in metabolic cages for the last three weeks of the 14 wk of treatment. Samples were collected from the metabolic cages and transferred immediately into sterile tubes. After the last administration at week 14, rats were fasted for 12 h and then anesthetized with chloral hydrate. Fasting blood was collected from the hepatic portal vein, and the liver was harvested and stored at 80 ℃ until use. Blood samples were allowed to clot at 4 ℃ and centrifuged at 10000 g for 10 min, after which serum was collected and stored at 80 ℃ until assayed.
Measurement of lipid parameters in serum and liver
TG and TC concentrations were determined using 100 μL of serum and 100 μL of liver homogenate supernatant, in which the protein concentration was measured by BCA assay. All parameters were evaluated on a SpectraMax Plus 384 Microplate Reader (Molecular Devices, Sun nyvale, CA, United States) using commercially available diagnostic kits in accordance with the manufacturer's instructions. 
Sample pre-treatment for UHPLC/MS analysis
Statistical analysis
Lipid concentrations in serum and liver are expressed as the mean ± standard deviation (SD). Statistical analyses were performed using SPSS software (13.0 for Windows; SPSS, Chicago, IL, United States). Differences between groups were analyzed by oneway analysis of variance (ANOVA, Dunnett's method). P < 0.05 (twotailed) was considered statistically significant.
All UHPLC/MS raw files were exported in Xcalibur Raw File (.raw) format and converted to computable docu ment format (.cdf) with Xcalibur 2.0 software (Thermo Fisher Scientific, Waltham, MA, United States). The converted file was then transferred into XCMS online (https://xcmsonline.scripps.edu) to output all data, inclu ding groups and comparisons. After that, multivariate statistical analysis, including principal components ana lysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA), was performed on SIMCA-P 14.1 software (Umetrics, Umeå, Sweden). Potential biomarkers were selected according to the parameters of variable importance in the projection (VIP > 1.0) from OPLS-DA. The metabolites were identified using METLIN database and compared with data reported previously. Finally, biochemical reactions involving the identified metabolites were found through the Kyoto Encyclopedia of Genes and Genomes (KEGG) in MetaboAnalyst4.0 online (http://www.metaboanalyst.ca).
RESULTS
Effects of HFD and P. kingianum on body weight and food intake
In the present study, a HFD rat model was used to in vestigate the potential effect of P. kingianum on HFD mediated dyslipidemia that was induced by admini stration of an HFD over a 14wk period. P. kingianum extract was administered by oral gavage at s dosage of 4 g/(kg•d) during HFD administration. During the experiment, none of the rats died, and they had healthy looking fur, normal drinking habits, moved freely and rapidly responded to external stimuli. As shown in Table 1 , the HFD slightly increased body weight, but P. kingianum and simvastatin showed a non-significant effect on body weight and food intake.
Effects of P. kingianum on lipids in serum and liver samples from HFD-fed rats
The effects of P. kingianum on lipids in serum and liver samples were first assessed in a rat model of HFD induced dyslipidemia. As shown in Table 2 , 14 wk of HFD feeding resulted in a significant increase in TC concentration, but had no significant effect on TG con- centration in serum. These effects were significantly reduced by simvastatin, which is known to correct dyslipidemias [15] . Similar to simvastatin, P. kingianum re markably prevented HFDinduced dyslipidemias. Further more, Table 3 shows that after 14 wk of HFD feeding, hepatic TC and TG concentrations were significantly increased compared with the normal control group. However, these effects were significantly reduced by P. kingianum and simvastatin treatment.
Metabolomic profiling of serum, urine and liver samples
Separation conditions of the three samples on the UHPLC column were optimized in terms of peak number, peak shape and reproducibility. Figures 35 shows representative total ion current profiles of the positive and negative ion modes of the four groups in serum, urine and liver, respectively. A large number of molecules were profiled by UHPLC/MS in the analyzed samples. Moreover, there were significant differences in peak number and intensity between the four groups within each of the three sample types. This indicated different metabolomic states in the different groups. Hence, after 14 wk of HFD feeding and administration of P. kingianum and simvastatin, the metabolites in serum, urine and liver samples were significantly different.
Multivariate statistical analysis of metabolomic data
PCA and OPLS-DA are frequently used for multivariate data analysis because of their ability to cope with highly multivariate, noisy, collinear and possibly incomplete data. PCA is an unsupervised pattern recognition method that is initially used to discern the presence of inherent similarities in profiles. OPLS-DA is a supervised pattern recognition approach based on a partial least squares algorithm that has higher sensitivity for biomarker detec tion than other methods. Figure 6A shows the PCA score plots of serum samples in positive and negative ion modes. The normal control, model, simvastatin and P. kingianum groups were lo cated in four different regions of the scatter score map. The four sample sets were basically separated. Additio nally, the P. kingianum group was closer to the normal group than the simvastatin group and partially over lapped with the normal group. This indicated that the composition and concentration of metabolites in the P. kingianum group was more similar to the control group. Thus, P. kingianum treatment remarkably prevented HFDinduced pathological changes.
Serum samples
OPLS-DA was performed to further verify sample separation from the four groups, to maximize separation between groups and to identify biomarkers from them ( Figure 6B ). The OPLS-DA score plots were described by the crossvalidation parameter, R 2 Y, and Q 2 , which represent the total explained variation for the X matrix and the predictability of the model, respectively. In posi tive and negative ion modes, the four groups were also significantly separated. The P. kingianum and simvastatin groups were both close to the control group, which fur ther indicated that P. kingianum treatment strongly pre vented HFDinduced pathological changes.
To further evaluate the component changes after treatment, an SPlot loading diagram was established based on OPLS-DA. As shown in Figure 6C , each point represents a variable that shows the biomarker that caused the difference between the model and P. kingianum groups. The importance of each variable to the classi fication was evaluated by the VIP value, with molecules with a VIP > 1.0 selected as potential biomarkers. Figure 7A shows the PCA score plots of urine samples in positive and negative ion modes. The control group was clearly distinguished from the other three groups, which overlapped partially. In the negative ion mode, there were abnormal sets in the control group, which might be due to individual sample differences that resulted in outlier sample points being outside the 95% confidence interval. The model group was significantly different from the control group. The P. kingianum and simvastatin groups had a tendency to deviate from the model group, while the P. kingianum group was closer to the cross than the simvastatin group. Compared with the model group, the P. kingianum group had a tendency to approach the part samples of the control group and deviate from the part samples of the control group. This was because the appearance of the outlier sample points seriously affected the clustering result. In the positive ion mode, outlier sample points appeared in the control group. The model group had a tendency to deviate to the left compared with the control group. The P. kingianum group partially overlapped with the simvastatin group, but did not approach the control group. This was considered to be related to the outlier sample points of the control group. Figure 7B shows the OPLS-DA diagrams of urine samples in positive and negative ion modes. The results suggested that the samples from all groups were perfectly separated, and samples in each group were well clustered. The model group was significantly different from the control group, indicating that physiological metabolism in the urine of rats was seriously interfered with by the HFD. The sample points of the P. kingianum group showed a tendency to approach the control group, indicating that HFDinduced changes were relieved after P. kingianum administration. Figure 7C shows the SPlot loading diagram of urine samples and the substances with a VIP > 1.0 that were selected as biomarkers. Figure 8A displays the PCA score plots of liver samples in positive and negative ion modes. In the negative ion mode, all samples were distributed within the 95% confidence interval. The control group partially over lapped with the model group, which might be due to the unsupervised pattern recognition of PCA analysis. In the positive ion mode, there were outlier sample points in the control group. The P. kingianum group was signi ficantly different from the control and model groups, indicating that P. kingianum administration interfered with metabolism in the rats. Figure 8B showed the OPLS-DA diagrams of liver samples in positive and negative ion modes. The results suggested that the samples from all groups were per fectly separated, and the samples in each group were well clustered. The P. kingianum group was closer to the control group than the simvastatin group, which indicated that P. kingianum had significant effects on metabolomic changes in the liver. Figure 8C shows the SPlot loading diagrams of urine samples and the substances with a VIP > 1.0 that were selected as biomarkers.
Urine samples
Liver samples
Potential biomarker identification
Nineteen compounds were identified from serum samples, including four in the negative ion mode and 15 in the positive ion mode. They were amino acids, carbo hydrates and esters (Table 4 ). There were 24 compounds identified from urine samples, including seven in the negative ion mode and 17 in the positive ion mode. They were amino acids, organic acids and esters (Table 5) . Finally, 38 compounds were identified from liver samples, including 18 in the negative ion mode and 22 in the positive ion mode. They were amino acids, organic acids and esters (Table 6 ).
Metabolic pathway analysis
Pathways with influence values greater than 0.1 were selected as the metabolic pathways [16] . Pathway impact plots were built to visualize the impact of altered meta bolic pathways ( Figure 9A ). According to these, the major intervening pathways in serum samples involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and phenylalanine, starch, sucrose, glycerophospholipid, tryptophan and tyrosine metabolism ( Figure 9A , Table 7 ). In urine samples, the major intervening pathway involved arachidonic acid metabolism ( Figure 9B , Table 8 ). In liver samples, the major intervening pathways involved phenylalanine, tyrosine and tryptophan biosynthesis, and arachidonic acid, linoleic acid, nicotinate, nicotinamide, sphingolipid, trypto phan and tyrosine metabolism ( Figure 9C , Table 9 ).
DISCUSSION
Dyslipidemia is mainly characterized by an increase in TC and TG concentrations in the serum and/or liver. We found that HFD feeding resulted in a significant increase in TC concentration in serum, and in TC and TG concen trations in the liver. This indicated that an HFD could induce hyperlipidemia. P. kingianum extract significantly inverted these HFDinduced changes, demonstrating that P. kingianum effectively ameliorated dyslipidemia in HFD fed rats. Additionally, due to fundamental differences in plasma lipoprotein metabolism between rats and hu mans, it is valuable to use an optimal pathological model to evaluate the lipidregulating effects of P. kingianum.
Metabolomics has been applied widely to the research of drug efficacy and the associated mechanism of ac tion [17] . Currently, the most common samples analyzed in metabolomics are serum, urine, tissues/organs, feces, cells and subcells. We used serum, urine and liver samples for metabolomic analysis. The liver is the most important locus for substance metabolism, and also the main site for lipid and amino acid metabolism. External stimuli (e.g. a drug) may cause hepatic metabolites to change affecting the physiological function of the liver [18] . Serum reflects the overall status of an organism. When metabolic abnormalities occur in the liver, the metabolites in blood may change through the blood circulation. Urine is an important excretion pathway for metabolites and contains abundant metabolomic information about an organism. Eleven main metabolic pathways affected by P. kingianum administration were found in the three samples, including seven in serum and in the liver, and one in urine (Figure 10 ).
Phenylalanine, tyrosine and tryptophan biosynthesis and metabolism
Amino acids are the body's raw material for protein syn thesis and are catabolic products. They participate in a variety of physiological and pathological processes, and their concentration often reflects the metabolic status of the body. In this study, a number of amino acid meta bolic pathways were present in the serum and liver sam ples, with a decrease in these metabolites, indicating disordered amino acid metabolism. Dyslipidemia causes dysfunctional phenylalanine metabolism by inhibiting conversion of phenylalanine to tyrosine, which in creases phenylalanine concentration in the blood. After P. kingianum administration, we showed decreased phenylalanine and increased tyrosine content in serum. Tyrosine is synthesized from phenylalanine and is neces sary for synthesizing catecholamine hormones such as adrenaline (epinephrine). It also plays an important role in promoting energy metabolism, scavenging free radicals and relieving fatigue [19] . Tyrosine undergoes a series of metabolic reactions to form acetylCoA, which participates in the tricarboxylic acid (TCA) cycle. After P. kingianum administration, the tyrosine content was increased, which elevated the acetylCoA content and further accelerated lipid decomposition through the TCA cycle. Therefore, P. kingianum treatment reduced phenylalanine production and further increased tyrosine production by regulating phenylalanine, tyrosine and tryptophan biosynthesis, and phenylalanine and tyrosine metabolism.
Tryptophan, an essential amino acid for humans, has important functions for regulating lipid metabolism [20] . In addition, tryptophan can be converted to acetyl CoA to participate in the TCA cycle. After P. kingianum administration, the tryptophan content was increased, which potentiated acetylCoA content and accelerated lipid decomposition. Thus, P. kingianum treatment in creased tryptophan content and further relieved the dis ordered lipids by regulating tryptophan metabolism.
Valine, leucine and isoleucine biosynthesis
Biosynthesis of valine, leucine and isoleucine was in volved in the serum samples. These amino acids can be broken down into glucose. We found that isoleucine was decreased by P. kingianum treatment, indicating a reduction in blood glucose. This affected the oxidation and decarboxylation of pyruvate, and further reduced lipid synthesis with glycerol to alleviate the lipid metabolic disorders. polysaccharide that is composed of several glucose units. Sucrose is a disaccharide comprised of glucose and fructose molecules. Both sucrose and starch can be broken down into glucose by digestive juice. Glucose can be degraded to dihydroxyacetone phosphate by glycolysis. Dihydroxyacetone phosphate can be reduced to glycerol and can also be converted to pyruvate through glycolysis. Pyruvate is converted by oxidation and decarboxylation to acetylCoA, which can be used to synthesize fatty acids and further synthesize fat with glycerol [21] . We found that glucose content was reduced after P. kingianum administration, which signified that P. kingianum reduced lipid synthesis by regulating starch and sucrose metabolism. 
Starch and sucrose metabolism
Glycerophospholipid metabolism
Glycerophospholipid metabolism was involved in the serum samples. Phosphatidylcholine is the molecule from this pathway that was significantly changed after P. kingianum treatment. It is an important component of lipoproteins, a precursor of synthetic cholesterol and it facilitates cholesterol dissolution in bile [22] . Phosphati dylcholine can also disintegrate TGs and cholesterol in blood and in vascular walls, reducing lipid deposition in the vessel walls. It has been reported that people who eat a highcholesterol diet with added phosphatidylcholine had lower blood cholesterol concentrations, supporting a hypolipidemic effect of phosphatidylcholine [23] . Fat is mainly transported by lipoprotein, while phospha tidylcholine is a vital substance for lipoprotein syn thesis. Increased phosphatidylcholine content leads to accelerated hepatic lipoprotein synthesis, which potentiates TG conversion. Thus, insufficient hepatic phosphatidylcholine synthesis is an important contributor to fatty liver. We found that the phosphatidylcholine content was significantly increased after P. kingianum treatment, demonstrating that P. kingianum regulated glycerophospholipid metabolism to relieve dyslipidemia.
Arachidonic acid metabolism
Arachidonic acid metabolism was involved in the urine and liver samples, and was significantly changed by P. kingianum treatment. Cell stimulation results in decom position of arachidonic acid into a free form by phospho lipase A2, with subsequent release into cytosol. The free form produces hundreds of bioactive metabolites by a series of metabolic enzymes. These metabolites have important regulatory effects on lipoprotein metabolism.
Arachidonic acid closely relates to development of hyper lipidemia. In addition to effectively reducing blood lipids, it also decreases malondialdehyde. The latter reflects the degree of lipid peroxidation in tissue cells, indica ting that arachidonic acid inhibits lipid peroxidation. Our 
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Dyslipidemia is an important risk factor for many vicious diseases such as diabetes and cardiovascular disease. Developing dyslipidemia regulators from traditional Chinese medicines (TCMs) to remedy lipid disorders represents attractive strategies for disease therapy. In China, Polygonatum kingianum (P. kingianum) has been used as an herb and nutritional food for centuries. Known pharmacological activities of P. kingianum include immune system stimulation, anti-aging effects and blood glucose regulation.
Research motivation
To date, studies on the effects of P. kingianum on dyslipidemia and the mechanism for these effects have not been investigated.
Research objectives
We aimed to identify the effects and mechanism of action of P. kingianum on dyslipidemia using an integrated untargeted metabolomic method.
Research methods
A rat model of dyslipidemia was induced with a high-fat diet (HFD) and rats were given P. kingianum [4 g/(kg•day)] intragastrically for 14 wk. Changes in serum and hepatic lipid parameters were evaluated. Metabolites in serum, urine and liver samples were profiled using ultra-high performance liquid chromatography/mass spectrometry followed by multivariate statistical analysis to identify potential biomarkers and metabolic pathways.
Research results
P. kingianum significantly inhibited the HFD-induced increase in total cholesterol
and low density lipoprotein cholesterol in serum, and total cholesterol and triglyceride in the liver. P. kingianum also reduced hepatic high density lipoprotein cholesterol. P. kingianum significantly regulated metabolites in the analyzed samples toward normal status. Nineteen, twenty-four and thirtyeight potential biomarkers were identified in serum, urine and liver samples, respectively. These biomarkers involved 11 main metabolic pathways, including seven in serum and in the liver, and one in urine.
Research conclusions
P. kingianum alleviated HFD-induced dyslipidemia by regulating many endogenous metabolites in serum, urine and liver samples. This involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and tryptophan, tyrosine, phenylalanine, starch, sucrose, glycerophospholipid, arachidonic acid, linoleic acid, nicotinate, nicotinamide and sphingolipid metabolism.
Research perspectives
P. kingianum may be a promising lipid regulator to treat dyslipidemia and associated diseases.
results showed increased arachidonic acid in the urine and liver samples after P. kingianum treatment. Thus, P. kingianum regulated arachidonic acid metabolism to alleviate dyslipidemia.
Linoleic acid metabolism
Linoleic acid metabolism was involved in the liver samples, and linoleic acid was significantly altered with P. kingianum treatment. Previous studies found that linoleic acid accelerated fatty acid oxidation and glucose decom position. Moreover, increased linoleic acid concentrations promoted proliferation and differentiation of fatty cells [24] . We found linoleic acid content to be significantly in creased after P. kingianum administration, suggesting that P. kingianum regulated linoleic acid metabolism.
Niacin and nicotinamide metabolism
Niacin and nicotinamide metabolism was involved in the liver samples. Nicotinamide was the molecule from this pathway that was significantly altered by P. kingianum treatment. Nicotinamide is a metabolite produced by amidation of niacin. Niacin reduces synthesis of low den sity lipoprotein cholesterol, TC and TG, and increases synthesis of high density lipoprotein cholesterol. This indicates that niacin regulates lipid metabolism [25] . Our results showed that niacinamide content was increased by P. kingianum treatment. This suggests that P. kingianum increases niacin to alleviate dyslipidemia by regulating hepatic niacin and nicotinamide metabolism.
Sphingolipid metabolism
Sphingolipid metabolism was involved in the liver sam ples. Sphingolipids regulate important cellular functions, with metabolic abnormalities in these lipids closely related to various diseases. Previous studies found that obese individuals have disordered sphingolipid metabolism, which appears as accumulation of sphingolipids (e.g., ceramide) in tissues and blood [26, 27] . Sphingolipids can be metabolized to sphingosine. In our study, sphingosine content was decreased after P. kingianum treatment, suggesting that P. kingianum might decrease sphingolipid content to alleviate dyslipidemia by regulating hepatic sphingolipid metabolism.
Conclusion
Taken together, our data indicated that P. kingianum extract alleviated HFDinduced dyslipidemia by regulating a large number of endogenous metabolites in serum, urine and liver. This involved phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine biosynthesis, and tryptophan, tyrosine, phenylalanine, starch, sucrose, glycerophospholipid, arachidonic acid, linoleic acid, nicotinate, nicotinamide and sphingolipid metabolism. Thus, P. kingianum may be a promising lipid regulator to remedy dyslipidemia and further alleviate its related diseases.
